Preserving Skeletal Muscle Tone in Inactive Patients

1969 ◽  
Vol 69 (12) ◽  
pp. 2662
Author(s):  
Leah Snyder Kinnaird
Keyword(s):  
1942 ◽  
Vol 137 (2) ◽  
pp. 251-255 ◽  
Author(s):  
W. F. Kiely ◽  
S. L. Hamilton ◽  
E. Gellhorn
Keyword(s):  

1990 ◽  
Vol 54 (1-8) ◽  
pp. 136-139 ◽  
Author(s):  
A. Struppler ◽  
T. Plant ◽  
M.T. Jahnke ◽  
H. Riescher

1969 ◽  
Vol 69 (12) ◽  
pp. 2662-2663
Author(s):  
LEAH SNYDER KINNAIRD
Keyword(s):  

2014 ◽  
Vol 8 (1) ◽  
pp. 17-22 ◽  
Author(s):  
Kornelia Tekes

Tolperisone (2-methyl-1-(4-methylphenyl)-3-piperidin-1-ylpropan-1-one hydro-chloride) was introduced in the clinical practice more than forty years ago and is still evaluated as a widely applicable compound in pathologically elevated skeletal muscle tone (spasticity) and related pains of different origin. In the present review, basic pharmacodynamic effects measured on whole animals, analyses of its actions on cell and tissue preparations and molecular mechanism of action on sodium and calcium channels are summarized as recently significantly new data were reported.


Stroke ◽  
2021 ◽  
Vol 52 (Suppl_1) ◽  
Author(s):  
Mate Gyimesi ◽  
Adam Horvath ◽  
Demeter Turos ◽  
Mate Penzes ◽  
Csilla Kurdi ◽  
...  

Post-stroke muscle spasticity affects 37% of stroke survivors and disables self-supporting life management. There is a high unmet medical need for an efficient antispastic drug because current muscle relaxants are often of limited efficacy and cause severe neurological and cardiovascular side effects due to targeting the central or peripheral nervous system. We developed a new-generation anti-spastic oral drug, MPH-220, which efficiently relaxes spastic skeletal muscles and lacks cardiovascular and neurological adverse effects because it selectively targets skeletal myosin, the contractile protein of muscles. MPH-220 is an efficient skeletal muscle specific actomyosin relaxant demonstrated on human muscle samples. Orally administered MPH-220 reduces muscle force of living rats without cardiovascular side effects. Brain-damage induced spastic animals showed drastic improvement in gait disorders upon oral MPH-220 treatment resulting in significantly straightened body posture, reduced number of spontaneous falling and cramping, and more ordered limb positions. Due to selective accumulation of MPH-220 in skeletal muscle tissues, antispastic effect was maintained for more than 10 hours. Due to its mechanism of action MPH-220 does not cause complete loss of muscle tone even at high doses. Furthermore, MPH-220 has excellent ADMET properties for oral administration: it is highly absorptive, non-mutagenic and has no effects on hERG channels, kinases, nuclear hormone receptors and GPCRs. Considering these results, MPH-220 is a promising anti-spastic oral drug candidate, which provides potential nervous system-independent therapies for spasticity and muscle stiffness without cardiovascular and neuronal side effects. Phase I clinical trials are scheduled for the beginning of 2021. Funded by the Hungarian National Research, Development and Innovation Office (NVKP 16-1-2016-0051 and PIACI-KFI-2019-00488).


Neurology ◽  
1992 ◽  
Vol 42 (5) ◽  
pp. 951-951 ◽  
Author(s):  
R. A. Davidoff

Sign in / Sign up

Export Citation Format

Share Document